Effect of Ciprofol on Postoperative Cognitive Function in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: A Prospective, Randomized, Controlled Trial.
Jun Lu, Yewei Shi, Xin Lan, Guangling Tang, Yi Shao, Chao Chen, Xinglong Xiong, Dongxu Chen, Jing Shi
{"title":"Effect of Ciprofol on Postoperative Cognitive Function in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: A Prospective, Randomized, Controlled Trial.","authors":"Jun Lu, Yewei Shi, Xin Lan, Guangling Tang, Yi Shao, Chao Chen, Xinglong Xiong, Dongxu Chen, Jing Shi","doi":"10.2147/DDDT.S536225","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the effects of ciprofol on postoperative cognitive function in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB).</p><p><strong>Patients and methods: </strong>A total of 138 patients who underwent cardiac surgery with cardiopulmonary bypass were included in this prospective, randomized, controlled study. Patients were randomized into two groups: the Ciprofol group (Group C) and the Propofol group (Group P). During anesthesia induction and maintenance, the patients in Group C received ciprofol, whereas those in Group P received propofol. The primary outcome measure was the incidence of postoperative delirium (POD), which was assessed twice daily for 7 days after surgery via either the Confusion Assessment Method (CAM) or the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Statistical analyses included chi-square tests for categorical outcomes and relative risk calculations for POD. Additionally, delirium subtypes were recorded. The incidence of postoperative cognitive dysfunction (POCD) was evaluated at 1 and 3 months after surgery using the Telephone Montreal Cognitive Assessment (T-MoCA). Furthermore, the occurrence of postinduction adverse events, including hypotension, bradycardia, and tachycardia, as well as the incidence of postoperative complications, were also documented.</p><p><strong>Results: </strong>POD occurred in 19/64 (29.69%) patients in the Ciprofol group and 34/65 (52.31%) patients in the Propofol group (RR = 0.57; 95% confidence interval = 0.37 to 0.88; <i>p</i> = 0.009). There was no significant difference in the incidence of POCD at 1 month (22.03% vs 26.62%, <i>p</i> = 0.547) or 3 months (16.25% vs 16.00%; <i>p</i> = 0.771) after surgery between the two groups.</p><p><strong>Conclusion: </strong>Ciprofol was found to decrease the incidence of POD in patients who underwent cardiac surgery with cardiopulmonary bypass. Nevertheless, no significant effect of this intervention on the incidence of POCD was demonstrated at either 1 or 3 months after surgery. A reduction in the incidence of delirium may be associated with improved postoperative recovery, shortened hospital stays, and a decrease in long-term cognitive impairments.</p><p><strong>Registration: </strong>The study had been registered in the Chinese Clinical Trials Registry (www.chictr.org.cn; Trial Identifier: ChiCTR2200061712).</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"7541-7552"},"PeriodicalIF":5.1000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406032/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S536225","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To investigate the effects of ciprofol on postoperative cognitive function in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB).
Patients and methods: A total of 138 patients who underwent cardiac surgery with cardiopulmonary bypass were included in this prospective, randomized, controlled study. Patients were randomized into two groups: the Ciprofol group (Group C) and the Propofol group (Group P). During anesthesia induction and maintenance, the patients in Group C received ciprofol, whereas those in Group P received propofol. The primary outcome measure was the incidence of postoperative delirium (POD), which was assessed twice daily for 7 days after surgery via either the Confusion Assessment Method (CAM) or the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Statistical analyses included chi-square tests for categorical outcomes and relative risk calculations for POD. Additionally, delirium subtypes were recorded. The incidence of postoperative cognitive dysfunction (POCD) was evaluated at 1 and 3 months after surgery using the Telephone Montreal Cognitive Assessment (T-MoCA). Furthermore, the occurrence of postinduction adverse events, including hypotension, bradycardia, and tachycardia, as well as the incidence of postoperative complications, were also documented.
Results: POD occurred in 19/64 (29.69%) patients in the Ciprofol group and 34/65 (52.31%) patients in the Propofol group (RR = 0.57; 95% confidence interval = 0.37 to 0.88; p = 0.009). There was no significant difference in the incidence of POCD at 1 month (22.03% vs 26.62%, p = 0.547) or 3 months (16.25% vs 16.00%; p = 0.771) after surgery between the two groups.
Conclusion: Ciprofol was found to decrease the incidence of POD in patients who underwent cardiac surgery with cardiopulmonary bypass. Nevertheless, no significant effect of this intervention on the incidence of POCD was demonstrated at either 1 or 3 months after surgery. A reduction in the incidence of delirium may be associated with improved postoperative recovery, shortened hospital stays, and a decrease in long-term cognitive impairments.
Registration: The study had been registered in the Chinese Clinical Trials Registry (www.chictr.org.cn; Trial Identifier: ChiCTR2200061712).
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.